Personalized Vancomycin Dosing for Children with Sepsis
This study is looking at whether personalized dosing of vancomycin, an antibiotic, can be improved for children with sepsis (a life-threatening response to infection). Researchers will use special models that consider new markers of kidney function to adjust vancomycin doses. The goal is to make sure children get the right amount of vancomycin to fight infection effectively while reducing the risk of kidney injury, a possible side effect. This study is for children aged 1 month to 17 years who weigh between 5kg and 50kg, are in the intensive care unit with suspected or confirmed sepsis, and are expected to receive vancomycin for at least 48 hours. The main goal is to see if this personalized dosing approach is practical to perform.
- Study design
- This is an interventional study, meaning participants will receive a specific treatment. It plans to enroll 20 children.
- What's involved
- Not specified in the trial record.
- Compensation
- Not stated in the trial record.
- Follow-up
- Participants will be followed from enrollment until 7 days after vancomycin therapy ends or for 30 days from enrollment, whichever is longer.
AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.
Vancomycin and Acute Kidney Injury in Sepsis Treatment - Intervention
At a glance
Conditions
Where it's being run
1 sites across 1 statesWho to contact
Opens a ready-to-send draft in your own email app — review before sending.
What this trial measures
- Feasibility - personalized dose adjustment performedFrom enrollment to the longer of 7 days after the completion of vancomycin therapy or through 30 days from enrollment
Percentage of enrolled patients in which urinary neutrophil gelatinase-associated lipocalin is measured and used to make a vancomycin dosing recommendation